- Home
- XERS vs ETW Comparison
XERS vs ETW Comparison
Compare XERS & ETW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XERS | ETW |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2021 | 2005 |
Fundamental Metrics
Financial Performance| Metric | XERS | ETW |
|---|---|---|
| Price | $6.37 | $9.46 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $10.83 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 238.3K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $49,590,000.00 | N/A |
| Revenue This Year | $34.37 | N/A |
| Revenue Next Year | $22.86 | N/A |
| P/E Ratio | $643.50 | ★ N/A |
| Revenue Growth | ★ 142.67 | N/A |
| 52 Week Low | $4.30 | $8.22 |
| 52 Week High | $10.08 | $9.60 |
Technical Indicators
Market Signals| Indicator | XERS | ETW |
|---|---|---|
| Relative Strength Index (RSI) | 54.88 | 58.40 |
| Support Level | $6.26 | $9.19 |
| Resistance Level | $6.41 | $9.57 |
| Average True Range (ATR) | 0.29 | 0.08 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 38.65 | 74.00 |
Price Performance
Historical ComparisonAbout XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
About ETW Eaton Vance Corporation Eaton Vance Tax-Managed Global Buy-Write Opportunites Fund of Beneficial Interest
Eaton Vance Tax-mangd Glo Buy-write Oppo is a United States-based diversified, closed-end management investment company. The primary investment objective of the company is to provide current income and gains. The secondary objective of the fund is capital appreciation. The fund invests in a diversified portfolio of common stocks and writes call options on one or more U.S. indices on a substantial portion of the value of its common stock portfolio to generate current earnings from the option premium. Its portfolio of investments consists of capital markets, chemicals, banks, biotechnology, media, and other sectors.